Evidence map›Paper›PMID 36806937›Full record

ArticleJournal of the National Cancer Institute2023

Smoking as a prognostic factor for survival in patients with disseminated germ cell cancer.

Mikkel Bandak, Kristine Skovly Nielsen, Michael Kreiberg, Thomas Wagner, Josephine Rosenvilde, Charlotta Pissinger, Christoffer Johansen, Gedske Daugaard, Jakob Lauritsen

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Mikkel BandakDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0003-3475-9675
Kristine Skovly NielsenDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Michael KreibergDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0001-5611-5163
Thomas WagnerDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-0256-0074
Josephine RosenvildeDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-7293-2339
Charlotta PissingerCenter for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Copenhagen, Denmark.
Christoffer JohansenLate Effect Research Unit (CASTLE), Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-4384-206X
Gedske DaugaardDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Jakob LauritsenDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Copenhagen University Hospital · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the impact of smoking on overall survival (OS) in testicular germ cell cancer (TC) patients receiving first-line combination chemotherapy (bleomycin-etoposide-cisplatin [BEP]). Patients who received BEP for metastatic TC were identified in the Danish Testicular Cancer database. Information on smoking status at the time of diagnosis was obtained by medical record review. OS and cause of death were compared between current smokers and never-smokers. Of 1883 eligible patients, information on smoking status was available in 1156 patients, of whom 602 were current smokers. The 10-year OS was 92% in never-smokers compared with 83% in current smokers (P < .001) (hazard ratio for death = 1.85, 95% confidence interval = 1.29 to 2.66, P = .001). A higher proportion of current smokers died of TC compared with nonsmokers (P < .01). Smoking negatively affects survival after BEP in patients with disseminated TC. Vigorous smoking cessation programs are advocated in TC patients.

Indexed as

Neoplasms, Germ Cell and EmbryonalTesticular NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBleomycinCisplatinEtoposideHumansMalePrognosisSmokingBleomycinCisplatinEtoposide

Identifiers

PMID36806937
PMCPMC10248846
OpenAlexW4321471257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.